WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018009604) CHIMERIC DENGUE/ZIKA VIRUSES LIVE-ATTENUATED ZIKA VIRUS VACCINES
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/009604    International Application No.:    PCT/US2017/040820
Publication Date: 11.01.2018 International Filing Date: 06.07.2017
IPC:
C07K 14/005 (2006.01), C12N 7/00 (2006.01), A61K 39/12 (2006.01)
Applicants: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES [US/US]; National Institutes of Health Office of Technology Transfer 6011 Executive Boulevard, Suite 325, MSC 7660 Bethesda, MD 20852-7660 (US)
Inventors: KINNEY, Claire, Y.H.; (US)
Agent: CONNOLLY, Jodi, L.; (US)
Priority Data:
62/359,812 08.07.2016 US
Title (EN) CHIMERIC DENGUE/ZIKA VIRUSES LIVE-ATTENUATED ZIKA VIRUS VACCINES
(FR) VACCINS DE VIRUS ZIKA À VIRUS DE LA DENGUE/ZIKA CHIMÈRE VIVANTS-ATTÉNUÉS
Abstract: front page image
(EN)Chimeric flaviviruses that include non-coding regions, non-structural proteins, a capsid (C) protein and a portion of a premembrane (prM) signal sequence from an attenuated or wild-type dengue serotype 2 virus (DENV-2), and a portion of a prM signal sequence, a prM protein and at least a portion of an envelope (E) protein from a Zika virus (ZIKV) are described. Also described are immunogenic compositions and methods for eliciting an immune response in a subject, such as an immune response directed against ZIKV.
(FR)La présente invention concerne des flavivirus chimères qui comprennent des régions non codantes, des protéines non structurelles, une protéine de capside (C) et une partie d’une séquence signal prémembranaire (prM) à partir d’un virus de la dengue atténué ou de type sauvage du sérotype (2) (DENV-2), et d’une partie d’une séquence signal (prM), d’une protéine (prM) et d’au moins une partie d’une protéine d’enveloppe (E) provenant d’un virus Zika (ZIKV). Sont également décrits des compositions immunogènes et des procédés permettant de déclencher une réponse immunitaire chez un sujet, telle qu’une réponse immunitaire dirigée contre le ZIKV.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)